^
    3years
    Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China. (PubMed, Pharmacology)
    These results suggest that EGFR 19-Del confers superior PFS and response to the icotinib treatment compared to 21-L858R.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L858R + EGFR exon 19 deletion • EGFR exon 21 mutation + EGFR L858R
    |
    Conmana (icotinib)
    over3years
    Analysis of Multigene Mutations in Lung Adenocarcinoma in Zunyi. (PubMed, Biomed Res Int)
    Although both mutations and multisite mutations in the other driver genes account for a low proportion, they still have great clinical significance. Multigene mutation detection contributes to the rapid screening of patients with lung adenocarcinoma who respond to targeted therapy.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK fusion • EGFR L861Q • ALK mutation • EGFR G719X • NRAS G13 • EGFR exon 21 mutation + EGFR L858R